The effect of oral pleconaril on hepatic cytochrome p450 3A activity in healthy adults using intravenous midazolam as a probe

Journal of Clinical Pharmacology

Volumn 46, Issue 1, 2006, Pages 103-108

  Ma, Joseph D ^a   Nafziger, Anne N ^a,b   Rhodes, Gerry ^c,d   Liu, Siyu ^b,c   Gartung, Anne M ^a   Bertino Jr , Joseph S ^a,b,e  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b ViroPharma Incorporated ^*  (United States)

^c ViroPharma Incorporated   (United States)

^d Gilead   (United States)

^e ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

CYP3A; Cytochrome P450; Pleconaril

Indexed keywords

CYTOCHROME P450 3A; MIDAZOLAM; PLECONARIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; ENTEROVIRUS INFECTION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; LEAST SQUARES GEOMETRIC MEAN RATIO; MALE; NORMAL HUMAN; REGRESSION ANALYSIS; RHINOVIRUS; SEDATION; SIDE EFFECT; VIRUS INFECTION;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MALE; MIDAZOLAM; OXADIAZOLES;

EID: 29644444394     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005283286     Document Type: Article

References (40)

1. Makela MJ, Puhakka T, Ruuskanen O, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998;36:539-542.
2. Chidekel AS, Rosen CL, Buzzy AR. Rhinovirus infection associated with serious lower respiratory illness in patients with bronchopulmonary dysplasia. Pediatr Infect Dis J. 1997;16:43-47.
3. Hayden FG, Coats T, Kim K, et al. Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials. Antiviral Ther. 2002;7:53-65.
4. Strikas RA, Anderson LJ, Parker RA. Temporal and geographic patterns of isolates of nonpolio enterovirus in the United States, 1970-1983. J Infect Dis. 1986;153:346-351.
5. Rotbart HA. Enteroviral infections of the central nervous system. Clin Infect Dis. 1995;20:971-981.
6. Rotbart HA. Human Enterovirus Infections. Washington, DC: American Society of Microbiology Press; 1994.
7. Billich A. Pleconaril Sanofi Synthelabo/ViroPharma. Curr Opin Investig Drugs. 2000;3:303-307.
8. Florea NR, Maglio D, Nicolau DP. Pleconaril, a novel antipicornaviral agent. Pharmacotherapy. 2003;23:339-348.
9. Kaiser L, Crump CE, Hayden FG. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antivir Res. 2000;47:215-220.
10. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. 1999;43:2109-2115.
11. Pevear DC, Seipel ME, Pallansch M, et al. In vitro activity of VP 63843 against field isolates of non-polio enteroviruses [abstract]. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996:181.
12. Hayden FG, Herrington DT, Coats TL, et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis. 2003;36:1523-1532.
13. Abdel-Rahman SM, Kearns GL. Single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults. J Clin Pharmacol. 1999;39:613-618.
14. Kearns GL, Abdel-Rahman SM, James LP, et al. Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Antimicrob Agents Chemother. 1999;43:634-638.
15. Rhodes G, Harling S, Hincks J. Effect of pleconaril on hepatic levels of CYP450 enzymes in rat and dog liver microsomes following in vivo dosing [abstract]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and chemotherapy. Chicago, Ill: American Society for Microbiology; 2001:13.
16. Bachmann K, White D, Jauregui L, et al. An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe. J Clin Pharmacol. 2003;43:1082-1090.
17. Rhodes G, Haughey D, Liu S. Effect of repeat doses of pleconaril on pharmacokinetics of theophylline in healthy adults [abstract]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Ill: American Society for Microbiology; 2001:13.
18. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB. The human CYP3A subfamily: practical considerations. Drug Metab Rev. 2000;32:339-361.
19. Streetman DS, Bertino JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10:187-216.
20. Abdel-Rahman SM, Kearns GL. Single-dose pharmacokinetics of pleconaril (VP63843) oral suspension and effect of food. Antimicrob Agents Chemother. 1998;42:2706-2709.
21. Kashuba ADM, Bertino JS, Rocci ML, Kulawy RW, Beck DJ, Nafziger AN. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther. 1998;64:269-277.
22. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics. 1994;4:171-184.
23. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol. 2003;43:443-469.
24. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther. 1994;271:549-556.
25. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther. 1981;30:653-661.
26. Lin YS, Dowling ALS, Quigley SD, Farin FM, Zhang J, Lamba J. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol. 2002;62:162-172.
27. Rogers JF, Rocci ML, Haughey DB, Bertino JS. An evaluation of the suitability of IV midazolam as an in vivo marker for hepatic CYP3A activity. Clin Pharmacol Ther. 2003;73:153-158.
28. Wilkinson GR. Cytochrome P450 3A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm. 1996;24:475-490.
29. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35:361-390.
30. Conney AH. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev. 1967;19:317-366.
31. Tang W, Stearns RA. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab. 2001;2:185-198.
32. US Food and Drug Administration, Center for Drug Evaluation and Research. Antiviral Drugs Advisory Committee. Available at: http://www.fda.gov/ohrms/ dockets/ac/cder02.htm#AntiviralDrugs.
33. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parrillo JE. Endotoxemia in human septic shock. Chest. 1991;99:169-175.
34. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318:1481-1486.
35. Ghezzi P, Saccardo B, Bianchi M. Recombinant tumor necrosis factor depresses cytochrome P-450 dependent microsomal drug metabolism in mice. Biochem Biophys Res Commun. 1986;136:316-321.
36. Shedlofsky SI, Swim AT, Robinson JM, Gallicchio VS, Cohen DA, McClain CJ. Interleukin-1 (IL-1) depresses cytochrome P-450 levels and activities in mice. Life Sci. 1987;40:2331-2336.
37. Shedlofsky SI, Israel BC, Tosheva R, Blouin RA. Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women. Br J Clin Pharmacol. 1997;43:627-632.
38. Morgan ET. Down-regulation of multiple cytochrome P450 gene-products by inflammatory mediators in vivo. Biochem Pharmacol. 1993;45:415-419.
39. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev. 1997;29:1129-1188.
40. Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther. 2000;67:32-43.